Aptamers for personal care applications

US11384357B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11384357-B2
Application numberUS-201916270937-A
CountryUS
Kind codeB2
Filing dateFeb 8, 2019
Priority dateJun 29, 2018
Publication dateJul 12, 2022
Grant dateJul 12, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention is directed to an aptamer composition comprising at least one oligonucleotide consisting of: deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, and mixtures thereof; wherein said aptamer composition has a binding affinity for one or more fungi species from the genus Malassezia.

First claim

Opening claim text (preview).

What is claimed is: 1. An aptamer composition comprising at least one oligonucleotide consisting of: deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, and mixtures thereof; wherein said aptamer composition has a binding affinity for one or more fungi species from the genus Malassezia wherein at least one oligonucleotide is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 100. 2. The aptamer composition of claim 1 , wherein said at least one oligonucleotide comprises one or more motifs selected from the group consisting of SEQ ID NO 101, SEQ ID NO 102, and SEQ ID NO 103. 3. The aptamer composition of claim 1 , wherein said at least one oligonucleotide comprises non-natural nucleobases. 4. The aptamer composition of claim 3 , wherein said non-natural nucleobases are selected from the group comprising hypoxanthine, xanthine, 7-methylguanine, 5,6-dihydrouracil, 5-5-methylcytosine, 5-hydroxymethylcytosine, thiouracil, 1-methylhypoxanthine, 6-methylisoquinoline-1-thione-2-yl, 3-methoxy-2-naphthyl, 5-propynyluracil-1-yl, 5-methylcytosin-1-yl, 2-aminoadenin-9-yl, 7-deaza-7-iodoadenin-9-yl, 7-deaza-7-propynyl-2-aminoadenin-9-yl, phenoxazinyl, phenoxazinyl-G-clam, and mixtures thereof. 5. The aptamer composition of claim 1 , wherein the nucleosides of said at least one oligonucleotide are linked by a chemical motif selected from the group comprising natural phosphate diester, chiral phosphorothionate, chiral methyl phosphonate, chiral phosphoramidate, chiral phosphate chiral triester, chiral boranophosphate, chiral phosphoroselenoate, phosphorodithioate, phosphorothionate amidate, methylenemethylimino, 3′-amide, 3′ achiral phosphoramidate, 3′ achiral methylene phosphonates, thioformacetal, thioethyl ether, and mixtures thereof. 6. The aptamer composition of claim 1 , where said derivatives of ribonucleotides or said derivatives of deoxyribonucleotides are selected from the group comprising locked oligonucleotides, peptide oligonucleotides, glycol oligonucleotides, threose oligonucleotides, hexitol oligonucleotides, altritol oligonucleotides, butyl oligonucleotides, L-ribonucleotides, arabino oligonucleotides, 2′-fluoroarabino oligonucleotides, cyclohexene oligonucleotides, phosphorodiamidate morpholino oligonucleotides, and mixtures thereof. 7. The aptamer composition of claim 1 , further comprising at least one polymeric material, wherein said at least one polymeric material is covalently linked to said at least one oligonucleotide. 8. The aptamer composition of claim 1 , wherein said at least one polymeric material is polyethylene glycol. 9. The aptamer composition of claim 1 , wherein the nucleotides at the 5′- and 3′-ends of said at least one oligonucleotide are inverted. 10. The aptamer composition of claim 1 , wherein at least one nucleotide of said at least one oligonucleotide is fluorinated at the 2′ position of the pentose group. 11. The aptamer composition of claim 1 , wherein the pyrimidine nucleotides of said at least one oligonucleotide are fluorinated at the 2′ position of the pentose group. 12. The aptamer composition of claim 1 , wherein said at least one oligonucleotide is covalently or non-covalently attached to one or more personal care benefit agents, wherein said one or more personal care benefit agents are selected from the group comprising: anti-fungal agents, cooling agents, natural extracts, peptides, enzymes, conditioning agents, scalp health agents, anti-frizz agents, gloss improving agents, hair strengthening agents, hair growth actives, artificial color preserving agents, perfumes, malodor absorbing agents, styling agents, chelants, hair coloring dyes, sebum absorbing agents, sebum modification agents, and mixtures thereof. 13. The aptamer composition of claim 12 , wherein said one or more personal care active ingredients are selected from the group consisting of antifungal agents. 14. The aptamer composition of claim 13 , wherein said one or more personal care active ingredients are selected from the group consisting of zinc pyrithione, piroctone olamine, ketoconazole, and selenium disulfide. 15. The aptamer composition of claim 1 , wherein said at least one oligonucleotide is covalently or non-covalently attached to one or more nanomaterials. 16. A personal care composition comprising at least one nucleic acid aptamer; comprising at least one oligonucleotide consisting of: deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, and mixtures thereof; wherein said at least one nucleic acid aptamer has a binding affinity for one or more fungi species from the genus Malassezia wherein at least one oligonucleotide is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 100 and comprising one or more personal care active ingredients. 17. The personal care composition of claim 16 , wherein said composition comprises at least two different nucleic acid aptamers; and wherein said at least two different nucleic acid aptamers have binding affinities for different epitopes of said one or more fungi species from the genus Malassezia. 18. An aptamer composition comprising at least one oligonucleotide consisting of: deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, and mixtures thereof; wherein said aptamer composition has a binding affinity for one or more fungi species from the genus Malassezia comprising at least one oligonucleotide is selected from the group consisting of SEQ ID NO 1 to SEQ ID NO 10.

Assignees

Inventors

Classifications

  • having six membered rings · CPC title

  • Imidazoles or their condensed derivatives, e.g. benzimidazoles · CPC title

  • Antidandruff preparations · CPC title

  • of the sugar · CPC title

  • Nucleosides; Nucleotides; Nucleic acids · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11384357B2 cover?
The present invention is directed to an aptamer composition comprising at least one oligonucleotide consisting of: deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, and mixtures thereof; wherein said aptamer composition has a binding affinity for one or more fungi species from the genus Malassezia.
Who is the assignee on this patent?
Procter & Gamble
What technology area does this patent fall under?
Primary CPC classification C12N15/115. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).